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SUMMARY – The use of complementary and alternative medicine (CAM) is high and increa-
sing worldwide. Patients usually use CAM in addition to conventional medicine, mainly to treat pain. 
In a large number of cases, people use CAM for chronic musculoskeletal pain as in osteoarthritis, 
back pain, neck pain, or fibromyalgia. Herewith, a review is presented of CAM efficacy in treating 
musculoskeletal pain for which, however, no scientific research has so far provided evidence solid 
enough. In some rare cases where adequate pain control cannot be achieved, CAM might be conside-
red in rational and individual approach based on the first general rule in medicine “not to harm” and 
on the utility theory of each intervention, i.e. according to the presumed mechanism of painful sti-
mulus and with close monitoring of the patient’s response. Further high quality studies are warranted 
to elucidate the efficacy and side effects of CAM methods. Therefore, conventional medicine remains 
the main mode of treatment for patients with musculoskeletal painful conditions.
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Introduction
The definition of complementary and alternative 
medicine (CAM) is broad and constantly changing. 
In different parts of the world, the term has different 
meaning, knowing especially the fact that one-third 
of the world’s population and more than half of the 
poorest people in Africa and Asia have no access to 
conventional medicine (CM) at all. The World Health 
Organization (WHO), as the umbrella institution for 
human health, defines CAM as “all forms of health 
care which usually lie outside the official health sec-
tor”1. A definition by Cochrane Collaboration is: 
“Complementary and alternative medicine (CAM) is 
a broad domain of healing resources that encompasses 
all health systems, modalities and practices and their 
accompanying theories and beliefs, other than those 
intrinsic to the politically dominant health system 
of a particular society or culture in a given histori-
cal period. CAM includes all such practices and ideas 
self-defined by their users as preventing or treating 
illness or promoting health and well-being. Boundar-
ies within CAM and between the CAM domain and 
that of the dominant system are not always sharp or 
fixed”2.
The use of CAM is high and increasing world-
wide3. According to the study by Eisenberg et al., the 
number of CAM users in the US increased in the pe-
riod from 1990 to 1997 by more than 50%4, while data 
from 2001 showed the number of CAM users in the 
adult US population to amount to 67%5. A more re-
cent study conducted by Callahan et al. revealed that 
as many as 82% of patients with arthritis followed in 
primary care and 90.5% of those followed by special-
ist had tried at least one complementary therapy for 
arthritis symptoms6. Longitudinal studies conducted 
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in Great Britain confirmed this trend7-12. According 
to the 1994 research by Fisher et al. in Western Eu-
rope, the percentage of population reporting use of 
CAM was between 20% (The Netherlands) and 49% 
(France)13. WHO reports that the number of patients 
in developed countries (including Western Europe) 
using at least one form of CAM is even 70%-80%14. 
As for Croatia, in the study by Čižmešija et al., 53.5% 
of patients treated by primary care used CAM in 
addition to conventional health care and more than 
half of the respondents (59.6%) informed their doctor 
about it15.
The most common reason for the use of CAM is 
pain. The large numbers of patients who are using 
CAM are suffering from chronic musculoskeletal 
pain16,17. The cause of chronic pain is usually multi-
factorial and complex. Immediate and complete re-
lief of chronic pain can often be an unrealistic goal, 
so it is necessary to establish realistic targets in the 
treatment of these patients. These imply a pain re-
lief approach according to the patient’s life situation 
(“patient specific context”), ameliorating the patient’s 
pain and/or improving the quality of life and improv-
ing the patient’s risk profile by diminishing his/her 
need of polypharmacy, invasive interventions and/or 
unproven alternative therapies18,19. This approach re-
quires a broader picture in dealing with pain through 
integrative medicine that combines CAM and CM. 
Most patients using CAM do not waive the services 
of CM6,20,21. However, according to a study conducted 
in Croatia, the most frequently mentioned cause of the 
use of CAM (with CM) is the need of a specific thera-
pist who will help them solve the problem which CM 
has not recognized or has not find a solution for22. 
CAM is carried out by doctors of medicine and 
other CAM practitioners (acupuncturists, chiroprac-
tors, Reiki practitioners, etc.). The status of these 
therapists is different in different countries. In the 
US, there is the National Center for Complementa-
ry and Alternative Medicine as part of the National 
Institutes of Health. In Croatia, they are gathered in 
the society of alternative therapists and healers of the 
Croatian Association for Natural, Energy and Spiri-
tual Medicine (Hrvatska udruga za prirodnu, energetsku 
i duhovnu medicinu, HUPED). Croatia still has no 
legal framework for CAM, although efforts are cur-
rently in progress to define this area. The legislation in 
the European Union (EU) is different from country to 
country and therefore the next steps in this area will 
certainly be towards harmonization of the CAM leg-
islation in all EU countries, especially having in mind 
the fact that the increasing use of CAM inevitably in-
creases the number of CAM side effects14. 
People with musculoskeletal pain consume a lot 
of different “natural health products” and other in-
terventions, the therapeutic efficacy, side effects and 
mechanisms of action of which have not yet been suf-
ficiently clarified. The aim of this review is to evaluate 
the efficacy and safety of CAM for the treatment of 
musculoskeletal pain. 
Acupuncture
Acupuncture is part of a larger system healing 
within the traditional Chinese medicine characterized 
by the insertion of fine, solid metallic needles into or 
through the skin at specific sites. It is more than 3000 
years old. According to the traditional interpretation, 
bioenergy in the body flows through the meridians, 
which connect the surface of the body with the in-
terior of the body, and the essence of acupuncture is 
that the stimulation of acupuncture points affects the 
“flow of energy”23. A contemporary “Western” medi-
cal science fails to recognize the traditional interpre-
tations of unblocking the “bioelectric magnetic force” 
(“QI”) through the invisible energy channels (merid-
ians) and tries to explain the possible analgesic effect 
of acupuncture through various neural, humoral and 
biomagnetic mechanisms such as changing neural in-
nervation (local anesthesia at the insertion site com-
pletely reverses the analgesic effect of acupuncture)24, 
by releasing endogenous opioids in the brainstem, 
subcortical and limbic structures25, by releasing ad-
enosine at the insertion site26 and/or by changing the 
blood flow27. In addition, when applying acupunc-
ture, certain central nervous system (CNS) changes 
were observed on the functional magnetic resonance 
imaging (MRI)28 and positron emission tomography 
(PET) scan29. It has been shown that acupuncture as 
an adjuvant therapy may have beneficial effects in var-
ious diseases and musculoskeletal conditions. The two 
most common acupuncture therapy treatments are for 
neck pain and low back pain. A systematic review of 
the literature showed moderate evidence that chronic 
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mechanical neck pain was more effectively treated 
with acupuncture than with inactive treatment, mea-
sured immediately after treatment and during short-
term monitoring (standardized mean difference -0.37, 
95% CI -0.61 to -0.12)30-34. There is limited evidence 
that, in the short-term period, acupuncture is more 
effective than massage33. In cases of neck pain with 
radicular symptoms, it was found that, again in the 
short-term period, acupuncture was more effective 
than waiting list control35. As for low back pain, the 
data do not allow firm conclusions about its effective-
ness for acute pain. For chronic back pain, acupuncture 
was more effective in reducing pain and accelerating 
functional recovery immediately after treatment and 
during short-term monitoring, leading to the conclu-
sion that in this indication it can be recommended as a 
supplement to other therapies36. A meta-analysis con-
ducted on studies with 6359 patients showed that real 
acupuncture was no better than “sham” acupuncture, 
but both were better than none, pointing out the im-
portance of the placebo effect of acupuncture37. The 
Cochrane Back Review Group paper, which included 
20 studies, also found that the short-term effect of 
acupuncture was significantly better when compared 
to waiting list control or when acupuncture was added 
to another intervention38. Acupuncture can reduce 
pain and improve joint function in patients with knee 
osteoarthritis (OA)39. In a systematic review of litera-
ture on the effect of acupuncture in rheumatoid ar-
thritis (RA), the authors found only two papers that 
met the methodological criteria and concluded that 
acupuncture showed no statistically significant effect 
on pain versus control group (relative improvement of 
8%), although a tendency of decreasing pain was re-
corded (4 points on a 1-100 scale)40,41. Based on the 
limited number of high-quality studies in fibromyal-
gia, the authors concluded that the treatment using 
real acupuncture was more effective than placebo 
acupuncture42. In order to reactivate and deactivate 
trigger points in the myofascial pain syndrome, “dry” 
injections and the injection of anesthetics had a simi-
lar effect43,44. It seems that some types of acupuncture 
are more effective in achieving analgesia than oth-
ers. This mainly refers to electroacupuncture, which 
strongly activates opioid and nonopioid analgesics45. 
A relevant study on the effect of electroacupuncture 
is the one by Man et al., where this method led to a 
significant reduction in knee pain 24 hours after the 
treatment, with relative improvement of 66.6% com-
pared to the placebo group. The relative improvement 
after 4 months was 5.1%, also in favor of the thera-
peutic group46. It is of note that acupuncture is a safe 
method with few side effects. Minor and transient 
complications were observed in approximately 5% of 
cases, while serious side effects are very rare47.
Yoga 
Yoga is generally regarded as a CAM approach to 
health in order to improve flexibility, muscular and 
mental strength, emotional stability, self-confidence 
and peace of mind48. A growing number of physicians 
and patients today recognize yoga as a complementary 
therapy option and try to incorporate it in the conven-
tional methods of treating musculoskeletal diseases49,50. 
One high quality study found that a 6-week training 
of Viniyoga (therapeutically oriented yoga) was slightly 
more effective than conventional exercise in chronic 
low back pain, with mean difference (MD) in Rol-
land Morris disability questionnaire (RMDQ ) of -1.8 
(95% CI -3.5 to -0.1) and was moderately better than 
self-care educational book MD in RMDQ being -3.4 
(95% CI -5.1 to -1.6)51. It has been shown that yoga 
has a beneficial effect in patients with knee OA as an 
addition to conventional treatment52,53. A recent study 
revealed yoga (Iyengar yoga) to have a positive effect in 
decreasing pain, functional joint impairment and de-
pression in patients with chronic back pain54. Moreover, 
it was shown that it could reduce the symptoms of hand 
OA55 and had beneficial effects in younger patients 
with RA56. In a report which included 11 studies (4 
randomized controlled trials (RCT) and 4 non-RCTs, 
heterogeneous methods of research, diagnosis and in-
tervention), the authors’ conclusion was that there was 
strong evidence that yoga reduced the symptoms of 
arthritis (swelling/tenderness of joints, pain) and dis-
ability, while reinforcing self-confidence and mental 
health57. There still remains the question of the impact 
of other different types of yoga (Bikram, Vinyasa) on 
musculoskeletal symptoms.
Manual Medicine
The field of manual medicine consists of manipula-
tion, mobilization, as well as massage and osteopathy.
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Manipulation is by definition the application of 
high velocity and low amplitude manual thrusts to 
the joints slightly beyond the passive range of joint 
motion58. Basically, in the spine it aims to change the 
mechanical behavior of the functional spinal unit. 
Mobilization is the application of manual force to the 
joints within the passive range of joint motion that 
does not include a thrust. In practice, manipulation 
and mobilization are mainly used in the same package 
of treatment. Although it is often related to chiroprac-
tic, spinal manipulation dates back to ancient times. 
Spinal manipulation is believed to have been practiced 
in China as far back as 2700 BC. Also, it is described 
in the Hippocrates’ papers59. In India, it was consid-
ered as an act of hygiene and it made part of surgery. 
The modern period of spine manipulation begins in 
1975, when the first scientific conference in the USA 
was held60. Manipulation and mobilization are most 
commonly used in treating back pain and neck pain, 
although there is still no consensus on the disorders 
which can be treated with manipulative techniques. It 
has been suggested that manipulation and mobiliza-
tion should be used in segmental intervertebral joint 
dysfunction, subluxation or functional spinal lesions 
(FSL). The result of successful manipulation is the re-
covery of normal function and decreasing the symp-
toms caused by FSL. A systematic analysis of 42 studies 
by Bronfort et al. reviewed the efficacy of spinal ma-
nipulation and mobilization in patients with chronic 
low back pain. The authors’ conclusion was that there 
was moderate evidence on spinal manipulation with 
strengthening exercises being as effective as the use of 
non-steroid anti-inflammatory drugs (NSAIDs) with 
therapeutic exercise (in the short-term and long-term 
follow-up). Furthermore, there was moderate evidence 
that mobilization was more efficient than therapeutic 
exercise, limited evidence that manipulation was bet-
ter than physical therapy and home exercises, and that 
it was as effective as chemonucleosis in cases of lumbar 
disk herniation, but less effective than therapeutic ex-
ercise after herniated disk surgery61. In their previous 
study, the same authors found moderate evidence that 
spinal manipulation had a better analgesic effect than 
mobilization and diathermy in patients with acute low 
back pain and limited evidence of faster recovery com-
pared to conventional physical therapy62. Van Tulder 
et al. reviewed 25 randomized studies regarding spi-
nal manipulation in patients with acute and chronic 
back pain. They concluded that spinal manipulation 
was more effective than placebo and equally effective 
as other conservative treatment methods for back pain 
(drugs, physical therapy, medical gymnastics and low 
back pain school)63. In another review, Assendelft et 
al. analyzed 39 RCTs and failed to find evidence that 
spinal manipulation was superior to other standard 
methods in the treatment of patients with acute or 
chronic back pain64. As for chronic neck pain, in a 
systematic review, moderate evidence was found that 
spinal manipulation and mobilization reduced pain in 
the short-term and long-term period65, and there was 
strong evidence for reducing pain and improvement of 
function when applying therapeutic exercise alongside 
with manipulation/mobilization66. Spinal manipula-
tion is the only CAM method for treating back pain 
incorporated in guidelines for the treatment of acute 
low back pain in some countries61. 
Massage is a soft tissue manipulation technique 
applied for a localized pain caused by fascial muscle 
tension67. It is part of standard therapy in physical 
and rehabilitation medicine, i.e. it is used in every-
day clinical practice. A systematic review of papers 
on the effectiveness of massage in reducing back pain 
showed its impact on subacute and chronic nonspe-
cific low back pain68, but its effect on neck pain was 
not proved69. In patients with knee OA it improved 
the function and decreased pain even in the long-term 
follow-up70. It was shown that massage could decrease 
pain and improve the quality of life in patients with 
fibromyalgia, in the short-term71.
Osteopathy is a manipulative technique with a 
broader view in order to restore proper musculoskele-
tal function of the body. Therefore, it is defined as “the 
science, arts and philosophy, which is based on pre-
cise palpatory procedures and well-defined principles 
(functional unity, homeostasis, self-regulation, a holis-
tic approach …)”. The founder of osteopathy was An-
drew Taylor Still, an American physician and surgeon 
who laid its foundations back in 1874. Compared to 
other manipulative techniques, there are much less of 
clinical studies concerning osteopathy. A small study 
found that patients in an osteopathic treatment group 
required significantly less medication (pain killers, 
anti-inflammatory agents and muscle relaxants, for 
all P<0.001) and used less physical therapy (P<0.05) 
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than standard medical therapy group72. Arienti et al. 
from the Italian Institute of Osteopathy claimed that 
osteopathic treatment was effective in reducing pain 
in patients with spinal cord injuries73. Because of the 
insufficiency of larger clinical studies and strong evi-
dence for the effectiveness of osteopathic treatment, a 
rational approach and restraint is suggested.
Static Magnets 
Static magnets are sold in different forms, e.g., 
incorporated into arm and leg wraps, mattress pads, 
bracelets, necklaces and shoe inserts74. They are mar-
keted with claims of effectiveness in reducing pain, 
although evidence of scientific principles of biological 
mechanisms to support such claims is very limited75,76. 
Static magnets industry is a multi-billion dollar indus-
try77. Although the exact mechanism in pain reduc-
tion is not certain, the proposed one is the attenuation 
of neuronal depolarization by shifting the membrane 
resting potential of nociceptive C fibers78 and/or pro-
motion of an increase in blood flow through the skin 
and the subcutaneous and muscular tissue79. A sys-
tematic review and a meta-analysis of 9 randomized 
placebo controlled trials failed to prove the efficacy of 
static magnets in pain reduction (weighted mean differ-
ence (WMD) on the 100-mm visual analog pain scale 
(VAS) was 2.1 mm, 95% CI 1.8 to 5.9 mm, P=0.29)75. 
A study by Richmond et al. investigated the effect of 
magnetic and copper bracelets (2 groups wearing mag-
netic bracelets with different levels of magnetism, one 
group wearing copper and one group wearing demag-
netized bracelets) over 16 months and concluded that 
there were no differences regarding pain, stiffness or 
physical function in patients with OA76.
Supplements
Glucosamine, chondroitin, diacerein
Glucosamine and chondroitin are parts of proteo-
glycans. It has been proposed that glucosamine stimu-
lates the production of glycosaminoglycans (the key 
structural components of cartilage) and normalizes 
the cartilage metabolism, inhibits its degradation and 
fibrillation, and have an anti-inflammatory effect, re-
sulting in a decrease of pain and other symptoms, i.e. 
improving/maintaining function, as well as retarding 
the progression of OA80,81.
A meta-analysis by Vlad et al. showed that the 
benefit from glucosamine and chondroitin was not 
proven, while glucosamine hydrochloride preparation 
alone was not efficacious82. In a recent systematic re-
view including 25 studies with 4963 patients, the Co-
chrane Collaboration reported that the effectiveness 
of glucosamine was limited to glucosamine sulfate but 
was not demonstrated for glucosamine hydrochloride. 
Differences between the preparations of the original 
manufacturer (Rottapharm) compared to the oth-
ers were also emphasized. Compared to placebo, the 
authors found a 22% decrease for pain and an 11% 
improvement of function (a change according to the 
initial value) by using Lequesne index, while, surpris-
ingly, there was no statistically significant positive ef-
fect on the dimension of pain, function and stiffness 
in the WOMAC questionnaire83. Similar to some in-
ternational guidelines, the stand of the Croatian So-
ciety of Rheumatology is that, along with other thera-
peutic modalities, it might be rational to try to treat 
patients with knee/hip OA with glucosamine and/or 
chondroitin, and if the obvious response fails after 6 
months, their usage should be stopped84.
Diacerein is a derivative of anthraquinone, which 
has an inhibitory effect of IL-1β in vitro. It also has 
a proven structural-modifying effect in patients with 
hip OA85,86 as well as a mild analgesic effect87,88. Diar-
rhea and flatulence are the most common side effects. 
In Croatia, diacerein is not registered.
Lipids
Avocado/soybean unsaponifiables (ASU) 
The most thoroughly investigated lipid mixture is 
Piascledine (Pharmascience, Inc., Montreal, Quebec, 
Canada). Piascledine consists of 1/3 avocado and 2/3 
non-saponified soybean, the oil fraction, which does 
not create soap after saponification. Four double-blind 
placebo-controlled studies and one systematic review 
evaluated the effect of avocado/soybean unsaponi-
fiables (ASU) on hip and knee OA89-93. Two three-
month RCTs, one for knee OA and hip OA89 and the 
other only for hip OA90, showed that 300 mg ASU 
once a day reduced the NSAID intake. A six-month 
RCT on the effect of ASUs on hip and knee OA con-
firmed its significant positive effect on OA symptoms 
when compared to placebo91. In a 2-year study on hip 
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OA, 300 mg once a day did not slow down narrow-
ing of the joint space width92. A systematic review of 
the impact of ASUs suggested further research be-
cause three RCTs confirmed its good performance, 
but a long-term RCT denied it93. The conclusion of 
recent studies points to the positive effect of ASUs for 
knee and hip OA94, as well as for rheumatoid arthritis 
(RA)95. 
Polyunsaturated fatty acids (PUFAs)
Polyunsaturated fatty acids (PUFAs) are classi-
fied as n-3, n-6 and n-9, depending on the position 
of the last double bond in the fatty acid chain. The 
main dietary PUFAs are n-3 (linolenic and eicosapen-
taenoic acid) and n-6 (linoleic and arachidonic acid). 
Omega 3 is found in soybean oil, canola oil, flaxseeds, 
walnuts and fish oils, whereas omega 6 can be found 
in safflower, corn, soybean, sunflower oils and meat. 
The modern western diet is relatively low in omega 3 
fatty acids and relatively rich in omega 6 acids in com-
parison with the western preindustrial societies and 
eastern countries diet. Laboratory and animal stud-
ies have shown that diet rich in omega 3 fatty acids 
may be beneficial for patients with joint diseases96. In 
a meta-analysis of placebo-controlled studies it has 
been concluded that omega 3 fatty acids can relieve 
joint in doses greater than 2.7 g for a period longer 
than 3 months, with a remark that studies were of 
variable quality97. According to the best evidence syn-
thesis in a meta-analyses that observed the products 
made from a lipid extract from New Zealand green 
lipped mussel (Perna canalicus) rich in omega 3 fatty 
acids, limited evidence for their efficacy in OA and 
other joint diseases has been shown98.
Cetyl myristoleate
Cetyl myristoleate (CMO) is the cetyl ester of 
myristolic acid. It has been identified as an anti-in-
flammatory agent and as an immune system modu-
lator. Two relevant trials have been performed until 
now. In the first RCT, oral CMO capsules were com-
pared with placebo capsules (six capsules/day over 68 
days of treatment) among 64 patients with chronic 
knee OA over 68 days of treatment. Patients treated 
with CMO capsules had a significantly increased knee 
flexion (10.1°) compared with the placebo group (1.1°) 
and function, but there was no difference in knee ex-
tension99. In the second trial, CMO topical applica-
tion was compared with placebo topical application 
among 40 patients with knee OA. Patients applied a 
standardized amount of cream over a 10- to 12-cm 
area two times daily for 30 days. Patients applying 
CMO cream demonstrated greater improvements in 
the range of movement and function and no major ad-
verse effects were reported100.
Phytochemicals and Plants (Extracts) 
Ginger (Zingiber officinale) and turmeric (Curcuma 
longa)
People with musculoskeletal pain consume a lot of 
different ‘natural health products’ therapeutic efficacy, 
toxicity and mechanisms of action of which have not 
yet been sufficiently clarified. Ginger and turmeric are 
herbs from the same family (Zingiberaceae). Ginger is 
a very popular spice produced in more than 100,000 
tons per year worldwide. In the traditional medicine of 
Japan, China and India, it is known and recognized for 
its anti-inflammatory effect on musculoskeletal diseas-
es101. Studies on the effect of ginger on musculoskeletal 
pain are contradictory. In some studies it was shown to 
be moderately more efficient than placebo in reducing 
symptoms in treating knee OA102,103; in one study, its 
efficacy did not differ from that of placebo in the first 3 
months, however, demonstrating superiority in the next 
3 months104, whereas in another study there was no dif-
ference in the efficacy when compared to placebo105. 
The most comprehensive reporting of adverse 
events found these in 59% of patients receiving ginger 
extract compared with 37% of those receiving place-
bo, with gastrointestinal events particularly relating to 
eructation, dyspepsia and nausea as most pronounced 
(45% of patients taksing Ginger vs. 16% of those tak-
ing placebo), although 70% of them were evaluated as 
mild. None of other trials has reported any overall ex-
cess in adverse events, although bad taste was reported 
in those taking ginger extract102.
Some preliminary studies showed that turmeric 
could somewhat improve symptoms in rheumatoid ar-
thritis, but at concentrations no greater than those to 
be taken with food106. So, ginger and turmeric are safe 
for consumption, but in small quantities have no prov-
en effect on chronic painful rheumatic conditions.
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White willow bark (Salix alba)
White willow bark contains salicin. Salicin is rap-
idly metabolized into salicylic acid, which is known 
to have analgesic, anti-inflammatory and antipyretic 
effects. The acetylated derivative of salicylic acid is 
Aspirin. 
In the first trial, willow bark extract (dose equiva-
lent to 240 mg salicin/day) was compared with placebo 
over a 2-week treatment period in 78 patients with hip 
or knee OA. There was a statistically significant dif-
ference in change in pain using the Western Ontario 
MacMaster Questionnaire (WOMAC) (willow bark 
14% reduction vs. placebo 2% increase; P<0.05)107. In 
the second trial in 127 patients with knee or hip OA, 
willow bark at the same daily dose as the first trial was 
compared with both placebo and diclofenac sodium 
100 mg/day over a 6-week period. Assessing pain by 
the WOMAC, willow bark was more efficacious in 
reducing pain than placebo (47 vs. 17%) and no differ-
ent from diclofenac sodium (10%)108. Adverse effects 
such as increased blood pressure, stomach upset and 
allergic reactions were reported. 
Devil’s claw (Harpagophytum procumbens)
Devil’s claw (Harpagophytum procumbens) is a South 
African plant that grows in the regions bordering the 
Kalahari. Secondary tuberous roots are used to pre-
pare powders of extracts based on the content of har-
pagoside, which is thought to have anti-inflammatory 
and anti-degradation effects. This herbal medicine, 
at a dose of six capsules/day (each containing 435 mg 
cryoground powder), was compared with diacerein100 
mg/day for a period of 4 months in 122 patients with 
hip and knee OA. Over the course of the study, there 
was improvement in pain and disability, but with no 
difference between treatments. Subjects taking devil’s 
claw reported lower use of analgesics and NSAIDs. 
There were significantly fewer adverse event reports in 
the devil’s claw group (16 vs. 34%) than in diacerein 
group109.
Chili pepper (Capsicum frutescens)
Chili (spicy, cayenne) pepper contains capsaicin, 
which has analgesic effects. In Europe and America, 
topical preparations containing cayenne pepper are 
mainly used for the relief of pain associated with os-
teoarthritis, rheumatoid arthritis, sore muscles and 
joints, and for improving the circulation110.
According to the Cochrane Back Group study, 
white willow bark, devil’s claw and chili pepper have 
significant effects in reducing pain in patients suffer-
ing from low back pain compared with placebo111. Re-
cent studies showed moderate evidence of effective-
ness of white willow bark in reducing pain in patients 
with low back pain who took salicin in a dose of 240 
mg for 6 weeks112, as well as reduction of pain after 
using capsaicin for OA pain113. 
Pine bark
This herbal extract has been tested in the treatment 
of knee OA. In the first trial including 100 patients, 
after 3 months of treatment with Pycnogenol 150 mg 
daily, the patients reported reduced pain (P<0.04) and 
improvement in function (P<0.05), whereas those on 
placebo demonstrated no change114. In the second 
trial that included 156 patients who were taking Py-
cnogenol 50 mg twice daily also reported significant 
improvements in function, whereas there were no 
changes in the placebo group. They also demonstrated 
a decreased use of NSAIDs (58% vs. 1% reduction) 
and consequently of gastrointestinal complications 
(63% vs. 3% reduction)115. No serious adverse effects 
were noted on Pycnogenol in either trial.
Rose hip
The efficiency of this herbal medicine has been 
tested against placebo in three studies in patients with 
OA, with sample sizes ranging between 94 and 112 
116-118. The tested doses were 1 g for 4 months, 5 g of 
Hyben Vital (a standardized powder) for 3 months and 
the same preparation for 4 months. In all three tri-
als, there were at least some positive results regarding 
the use of rose hip. In a cross-over trial that included 
patients with OA of several sites, there was a high-
ly statistically significant difference just for the first 
treatment period, an effect that the authors viewed as 
signaling a strong carry-over effect116. In the second 
trial in patients with hip or knee OA, at the end of the 
3-month follow-up there was a significant improve-
ment in those taking rose hip regarding performing 
activities of daily life, stiffness, patient global assess-
ment, although there was no significant difference 
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in pain117. In the last trial that also included patients 
with knee or hip OA, both pain and hip range of mo-
tion (although not the knee range of motion) had im-
proved more in the rose hip group118. None of the tri-
als reported any difference in adverse events between 
the groups.
Boswellia serrata (Indian roots)
Its efficacy in knee OA was tested in three RCTs119-
121. The first trial was a placebo controlled trial with a 
cross-over design, involving 30 patients. When receiv-
ing Boswellia (B.) serrata, the patients demonstrated 
significantly greater reduction in pain, swelling and 
improvement in function over 8-week treatment with 
333 mg of the product three times daily. The second 
trial tested 5-Loxin, which is an extract of B. serrata 
enriched with 30% 3-O-acetyl-11-keto-beta-boswell-
ic acid. Seventy-five subjects received 100 or 250 
mg 5-Loxin, or placebo, for 90 days. Both doses of 
5-Loxin conferred significant pain and function im-
provement compared with placebo (P<0.0001 for both 
doses). In the last trial, B. serrata 333 mg three times 
daily was tested against valdecoxib 10 mg once daily 
for 6 months. At the end of the study, both B. serrata 
and valdecoxib demonstrated significant reduction 
in pain from baseline and the latter also in function 
(P<0.001 all). One month after stopping treatment, 
the group taking B. serrata demonstrated maintained 
improvement regarding pain and function (P<0.001). 
There were no serious adverse events reported in any 
study nor were adverse events of any sort significantly 
more common in the groups taking B. serrata. 
Flavonoids, Uncaria, bromelanin
For some other plants or their ingredients, such 
as flavonoids (polyphenolic compounds in plants: tea-
containing cathesins, soy isoflavonoids), Uncaria tom-
enosa and Uncaria guianensis (cat’s claw, extract from 
root and inner bark of a South American vine), no 
evidence was found or there was the lack of evidence 
for their efficiency122.
Regarding bromelanin, which is an extract from 
both the stems and immature fruits of the pineapple 
plant, which contains a number of proteolytic en-
zymes with anti-inflammatory, analgesic, antiedema-
tous, antithrombotic and fibrinolytic effects, limited 
evidence was found for its effectiveness in OA, while 
it may have negative effect on cardiac rhythm96.
Cannabis
There are many differences of opinion regarding 
the use of cannabis for medical purposes. A study 
conducted in The Netherlands was in favor of smok-
ing cannabis for medical purposes123. Result was good 
to excellent reduction in symptoms in most patients 
(64%) with neurological and musculoskeletal dis-
eases and cancer anorexia/cachexia, with mostly mild 
side effects. A recent study by Ware et al. showed 
that smoking marijuana can reduce neuropathic pain 
and posttraumatic postoperative pain measured on 
an 11-point scale (5.4:6.1 MD, 95% CI 0.02 to 1.4; 
P=0.023) and improve sleep (P<0.05), at least for 3 
months124. The prevalent attitude is that in spite of 
moderate effectiveness of treating chronic pain with 
cannabis, it is still considered inferior to its poten-
tial harm125. A study by Xu et al., published this year, 
stated the ability to treat neuropathic pain with new 
drugs which target the CB2 receptors mostly located 
in the peripheral immune system (as opposed to CB1 
receptors, which are mostly in the brain)126. It opens 
new opportunities to create drugs with fewer side ef-
fects in treating this kind of pain.
Pomegranate, green tea, grapes 
Pomegranate, green tea and resveratrol from grapes 
are examples of compounds whose possible analgesic 
and anti-inflammatory mechanisms have been recently 
elucidated in the article by Khalife et al. 127. Standard-
ized Pomegranate Extract (PE) specifically reduces 
certain biochemical factors whose cascade regulates 
the anti-inflammatory genes and can potentially re-
duce cartilage destruction in OA128. The anti-arthritic 
effect of green tea may be attributed to the epigallo-
catechin-3-gallate (EGCG) and can result in reduced 
synovial hyperplasia, cartilage degradation and bone 
resorption by protecting human chondrocytes from 
IL-1β induced inflammatory responses129,130. Res-
veratrol from grapes shows anti-inflammatory and 
chondroprotective activity by increasing proteogly-
can synthesis and proliferation of chondrocytes and 
therefore may act as prevention in intervertebral disk 
degeneration, inflammatory changes in OA, apoptosis 
of chondrocytes and pannus formation131.
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Articulin F 
This ayurvedic herbal preparation was tested in a 
cross-over study in 42 patients with symptomatic OA 
who also had radiological changes on the affected 
joints. After 3-month treatment with Articulin F or 
placebo two capsules daily allocated in random order, 
patients who received Articulin F had significantly 
better improvement in pain and function. However, 
there was no difference in joint structural changes ac-
cording to radiological evaluation. No adverse effects 
necessitating discontinuation of Articulin F have been 
reported132.
Eazmov capsules
This ayurvedic herbal preparation (Cyperus ro-
tundus, Tiospora cordifolia, Saussurea lappa, Picorrhiza 
kurroa and Zingiber officinale) was compared with di-
clofenac sodium, each 50 mg three times daily, in 31 
patients with OA. After 6 months of treatment, the 
patients who received Eazmov had less improvement 
in pain (P<0.001) and disability (P<0.05) comparing to 
diclofenac. However, significantly fewer adverse effects 
were reported by the patients allocated to Eazmov133.
Vitamins
Generally, vitamins are used as supplements in 
case of their deficiency. Some vitamins might have an 
impact on musculoskeletal diseases, mainly as anti-
oxidants. They are able to neutralize most kinds of re-
active oxygen species (ROS) with a degradation effect 
by enzymes such as superoxide dismutase, catalase 
and peroxidase, or by small antioxidant molecules. 
When ROS are produced in increased amounts as in 
OA, the antioxidant capacity of cells and tissues can 
become insufficient to detoxify the ROS, which then 
contribute to cartilage degradation by inhibiting ma-
trix synthesis, directly degrading matrix molecules or 
activating matrix metalloproteinases134. 
Vitamin C is mostly (80%-90%) found in food 
(rose hips, blackcurrant, citrus fruits), but can also 
be synthesized from glucose. The Framingham epi-
demiological study showed a threefold reduction in 
the risk of OA progression for the middle and highest 
tertiles of vitamin C intake, as well as a reduced loss 
of cartilage135. In a high-quality RCT, taking large 
amounts of vitamin C (2x1 g) led to a decrease of pain 
on the VAS scale by 4-6 mm (the baseline value was 
50 mm)136. However, regarding the recommendation 
of taking high doses of vitamin C, especially for older 
people who suffer from OA, there is the need of fur-
ther research which will look into the long-term ef-
fect, as well as in the safety of vitamin C.  
Vitamin E was tested (in its natural form in 8 
shapes or as α-tocopherol) in five RCTs. The results 
were divergent. Two studies showed that vitamin E 
was superior to placebo (vitamin E intake of 600 mg 
per day137 and 400 IU of α-tocopherylacetate once a 
day138), one showed that the effect of vitamin E (544 
mg α-tocopherylacetate) was equal to the effect of 
diclofenac (150 mg/day) on the VAS scale of pain139, 
while in two recent studies the efficacy of vitamin E 
was not better than placebo140,141. One of the richest 
food sources of vitamin E is edible plant oil.
The B-complex group includes choline and inosi-
tol as well as para-aminobenzoic acid that is naturally 
paired with B group vitamins142. The term B-complex 
was created because in the past it was believed that it 
was just one kind of vitamin found in the extract of 
rise, liver or yeast. Later, the vitamins were isolated 
and given numbers: B1 (thiamin), B2 (riboflavin), B3 
(nicotinic acid), B5 (pantothenic acid), B6 (pyridox-
ine), B9 (folic acid) and B12 (cyanocobalamine). Two 
older RCTs showed that high doses of B vitamins had 
no effect on pain143,144. In one trial, B complex was 
tested among 26 patients with hand OA who had been 
prescribed NSAIDs. The subjects were randomly al-
located to 6400 µg folate daily with or without 20 µg 
cobalamine or lactose placebo for a 2-month period. 
There were less tender hand joints and grip strength 
was greater in those receiving the folate-cobalamine 
combination143. In the other trial of niacinamide, 72 
patients took one tablet six times daily (total 3000 mg) 
or placebo for 12 weeks. Pain level did not change on 
placebo but was significantly reduced in those taking 
niacinamide, whereas the measurement of global ar-
thritis impact improved in those on niacinamide [-29% 
(95% CI -6, -46)] and significantly worsened in those 
on placebo145. In the latter trial, significantly more sub-
jects on niacinamide reported side effects (40 vs. 27%; 
P=0.03), mostly due to heartburn and nausea. 
In addition, there was no evidence that a cock-
tail of vitamins (A, C, D) and selenium reduced the 
symptoms of osteoarthritis142.
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Vitamin D is for historical reasons included in 
vitamins, although the majority of its characteristics 
indicate it is a hormone (steroid structure, mechanism 
of action)146. Vitamin D is considered a prohormone 
with different active metabolites that play an impor-
tant role in many physiological processes including the 
metabolism of bone and cartilage147, the muscles148, 
and lately an inverse correlation of its serum levels 
with disease activity in early polyarthritis149 has also 
been emphasized. A Framingham study found a three 
times greater increase in the risk of hip OA progres-
sion in the middle and lowest tertile of serum vitamin 
D150. A study on osteoporotic fractures in women no-
ticed an increased risk of incident hip OA (joint space 
narrowing), which might be associated with pain at 
medium and lowest tertile of serum vitamin D151. A 
research by the European Male Aging Study Group 
revealed that patients with musculoskeletal pain had 
lower levels of serum vitamin D152. Indirect effects of 
vitamin D on pain have been reported by Bishoff et 
al., as in their study the consumption of vitamin D 
(and calcium supplements) reduced the risk of fall by 
even 49%153.
Glucosides
Natural remedies that contain glucosides derived 
from white peony root extract are believed to have an-
ti-inflammatory, antioxidant and immunoregulatory 
effects. In the changed inflamed joints, a several-fold 
concentration of nitric oxide (NO) has been record-
ed, as well as increased activity of the enzyme that 
regulates its formation154,155. Glucosides inhibit the 
increased levels of NO in painful and inflamed joints 
and change its concentration back to normal levels, 
thus having the potential of reducing pain and stiff-
ness of the joints. Their effect is achieved at the mo-
lecular level, which has so far been proven in preclini-
cal studies156-158, although there are some encouraging 
studies with the observation of the favorable effect of 
total glucosides alongside with disease-modifying an-
tirheumatic drugs (DMARDs)159-161.
Methylsulfonylmethane (MSM)
Methylsulfonylmethane (MSM) is an organic sul-
fur compound, which is a precursor of dimethyl sul-
foxide (DMSO). It is found in very low amounts in 
fruits, corn, tomatoes, tea, coffee and milk. The effica-
cy of MSM in the treatment of knee OA was tested in 
three trials with sample sizes ranging between 50 and 
118 subjects162-164. In all trials, MSM (at doses of 1.5, 
3.375 and 6 g/day for 12 weeks) was found to be sig-
nificantly more effective in improving pain compared 
to placebo. It was also more effective in improving 
function in two trials162,163, and in the third one when 
combined with glucosamine164. Adverse events were 
either similar between MSM and placebo groups162,163 
or no adverse events were reported166. However, a 
meta-analysis of 3 high-quality studies by Brien et al. 
showed that current data could not support recom-
mendation for the use of MSM/DMSO in the treat-
ment of OA165.
S-adenosyl methionine 
The efficacy of S-adenosyl methionine (SAMe) in 
treating OA of the knee, hip or spine has been tested 
in six trials with sample sizes ranging between 36 and 
493166-171. In all trials, the dose tested was 1200 mg 
per day and the comparators were celecoxib 200 mg/
day (16 weeks of treatment), piroxicam 20 mg/day (12 
weeks), indomethacin 150 mg/day (28 days), ibupro-
fen 1200 mg/day (two trials, 30 days both), naproxen 
750 mg/day and placebo (30 days). In all trials, SAMe 
was found to be equivalent in efficacy as NSAID and 
more effective than placebo for pain and function 
where this was measured separately for a global score 
of which pain and function were a major part170,171. 
In a meta-analysis of the efficacy and safety, which 
included trials of i.v. administration, there was no sig-
nificant difference between the likelihood of patients 
taking SAMe and placebo to report adverse effect 
but patients taking SAMe were less likely to report 
an adverse event than those taking an NSAID (odds 
ratio (OR) 0.42; 95% CI 0.29 to 0.61). The drop-out 
rate in the trials was highest for those receiving an 
NSAID (6.9%), followed by placebo (5%) and lowest 
for SAMe (2.6%)172.
Topical rubefacients
Rubefacients (which contain salicylates and 
nicotinamides) cause skin irritation and are be-
lieved to reduce various musculoskeletal pain. 
A systematic review by Matthews et al. showed that 
according to the results of 7 RCTs (6 placebo and 1 
active controlled study) there was no evidence to sup-
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port the notion that topical rubefacients may suppress 
acute painful conditions. Regarding their effect on 
chronic pain, an analysis of 9 RCTs (7 placebo and 2 
active controlled studies) showed that they were not as 
effective as topical NSAIDs173.
Hyperimmune milk
In two RCTs, the effect of hyperimmune milk in 
OA was tested. This milk is produced by cows that are 
immunized with intestinal bacterial antigens in order 
to get milk with an increased concentration of high 
molecular weight immunoglobulins (IgG) and sup-
posed to contain anti-inflammatory low weight com-
ponents. The efficiency of hyperimmune milk has not 
been scientifically verified174,175.
Collagen hydrolysate
Collagen hydrolysate is generated by enzymatic 
degradation of gelatin, which itself is produced by hy-
drolysis of collagen extracted from animal bones and 
skin. In vitro, type I or type II collagen hydrolysate 
dose dependently increased type II synthesis by chon-
drocytes176. In mice, it accumulates in the articular 
cartilage177. Its effect on musculoskeletal symptoms 
has not been proven178,179.
Mind-Body Therapy
Mind-body therapies include cognitive behavioral 
therapy, hypnosis, biofeedback and mindfulness med-
itation. For many patients, the addition of a mind-
body approach to treating chronic pain has a ben-
eficial effect on their quality of life. From the above 
stated therapies, cognitive behavioral therapy is often 
included in the conventional treatment of chronic 
pain and relies on scientifically based knowledge and 
theories of cognition, emotions and behavior, their in-
teraction and possibilities to change180. The report of 
the Cochrane group (40 studies) showed that cogni-
tive behavioral therapy had a favorable effect on pain, 
disability and mood181.
Conclusion
There is an extremely large number of products 
and CAM interventions on the market today, which 
are mainly presented through the media as effective 
in treating musculoskeletal pain. The majority of data 
presented in this paper are of insufficient method-
ological quality, there is a striking paucity of RCTs, 
evidence is based on a small number of trials which 
generally included a small number of patients. One 
must take in consideration the publication bias favor-
ing papers with positive results. 
So, generally, with some exceptions, there is no 
solid enough scientific evidence to support the use 
of CAM in musculoskeletal painful conditions. To 
be able to clearly define the mechanism of action of 
most of the CAM interventions, additional high-
quality studies that deal with their molecular basis 
and mechanism of action are required, while clini-
cal data are missing too. On the other hand, most of 
CAM medications/interventions are free from major 
adverse effects and usually are associated with minor 
adverse effects. A rational attitude using them only 
in some situations when conventional medicine is not 
effective in controlling pain might be considered, but 
always keeping in mind the first rule of medicine “not 
to harm”. 
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Sažetak
KOMPLEMENTARNO I ALTERNATIVNO LIJEČENJE MIŠIćINOKOŠTANE BOLI
S. Grazio i D. Balen
Diljem svijeta zabilježen je porast učestalosti uporabe proizvoda i usluga komplementarne i alternativne medicine 
(KAM). Bolesnici primjenjuju KAM zajedno s metodama konvencionalne medicine i to prvenstveno za liječenje boli. 
U velikom broju slučajeva radi se o kroničnoj mišićnokoštanoj boli, primjerice kod osteoartitisa, križobolje, vratobolje ili 
fibromijalgije. U ovom se preglednom radu prikazuje učinkovitost KAM u liječenju mišićnokoštane boli, za koju zasada 
ne postoje čvrsti znanstveni dokazi. U nekih, i to rijetkih bolesnika u kojih se nikako ne može postići zadovoljavajuća 
kontrola boli eventualno bi se mogla razmotriti mogućnost primjene KAM u sklopu racionalnog i individualnog pristupa 
temeljenog na općem pravilu „ne štetiti bolesniku” i na korisnosti primjene tih metoda u pojedinog bolesnika, odnosno u 
skladu s pretpostavljenim mehanizmom bolnog podražaja, a uza strogo praćenje terapijskog odgovora. Postoji potreba za 
studijama visoke kvalitete kojima bi se razjasnilo pitanje učinkovitosti i nuspojava KAM. Stoga konvencionalna medicina 
ostaje glavni način liječenja bolesnika s bolnim mišićnokoštanim stanjima. 
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